Yahoo Finance published an article about Code Pharma and its intention to launch an Initial Public Offering (IPO) and list its shares on the NASDAQ and Switzerland’s SIX Swiss Exchange.
Code Pharma CEO and Founder, Zyon Ayni, said: “Today is a very exciting day for the Code Pharma team. We are well positioned to play a key role in the current race to develop a cure for COVID-19. Our drug Codivir – which was originally discovered at the Hebrew University in Israel – has a very good safety profile and very impressive antiviral activity, both under laboratory conditions and in our phase I clinical trials”.
Ayni added: “Also, Scientific data regarding Codivir’s mechanism of action strongly suggest that Codivir is effective against mutations of the Covid virus, including the recently discovered Omicron variant”.